Skip to main content
Premium Trial:

Request an Annual Quote

Quadrant Biosciences Licenses SUNY, Penn State Epigenetic Biomarkers for Neuro Diseases

NEW YORK (GenomeWeb) – Quadrant Biosciences said today that it has entered three new licensing agreements with SUNY Upstate Medical University and Penn State University for the global commercialization of epigenetic biomarkers for autism spectrum disorder, Parkinson's disease, and concussion.

The licensed biomarker technology is based on detection of RNA molecules in saliva, Quadrant said. The company has been working closely with both institutions for several years and has supported research studies that have confirmed high correlations between the expression of specific salivary RNAs and the presence of ASD, Parkinson's, and concussion.

The Syracuse, New York-based company did not detail which biomarkers it has licensed, but researchers from Penn State, working with Quadrant, have shown, for example, that miR-1277-5p is down-regulated in severe traumatic brain injury.

The first test that Quadrant plans to commercialize will be for ASD, the firm said. Financial and other details of the licensing were not disclosed.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.